iiinova — where your digital self keeps evolving

Lumanity @lumanity.bsky.social · 02/10/2026

Ed Saltzman will join venture capitalists, investors, and private equity experts on an insightful GCRIS panel; “Navigating the Nexus of Capital Markets, Cancer Innovation and Policy.” Learn more: buff.ly/yRR8ayI October 5, 2026 | 2:00pm – 2:50pm | New York, NY

010

Lumanity @lumanity.bsky.social · 02/10/2026

Jakub Kaczor, PhD and Peter Smith unpack the complexities of portfolio positioning and how to mitigate the risks of assets competing against each other in the same disease area. Watch now: buff.ly/wKE7Zj6

000

Lumanity @lumanity.bsky.social · 01/10/2026

Quick test: can two people on your team describe your target HCP behavior the same way? If not, you have a vague goal, not a defined behavior. Download the checklist to optimize your next brief: lumanity.com/perspectives...

000

Lumanity @lumanity.bsky.social · 01/10/2026

Jeff Bockman will join investors, VCs and private equity experts at the Global Cancer Research & Innovation Symposium panel; “Global Trends and Reality Checks on the State of Cancer Research.” Learn more: buff.ly/yRR8ayI October 6, 2026 | 8:00am – 9:00am | New York, NY

000

Lumanity @lumanity.bsky.social · 01/10/2026

Michael Rice will be in Phoenix for the Meeting on the Mesa! As a leader in the cell, gene and advanced therapy community, he's ready to discuss the latest advances, challenges and opportunities shaping this rapidly evolving field. Don't miss the opportunity to connect!

001

Lumanity @lumanity.bsky.social · 30/09/2026

Join us for Common Ground: When Patients, Providers and Pharma Build Partnerships That Last. Some of the most meaningful progress in healthcare happens when patients, advocates, providers, and pharma work toward the same goal. But holding that common ground is harder than it sounds. buff.ly/bOysufE

000

Lumanity @lumanity.bsky.social · 30/09/2026

Skip the guesswork. Get our Expert Navigator quick reference guide, watch the walkthrough, or request a custom demo—see the right experts, faster. lumanity.com/products/exp... #ExpertNavigator #MedicalAffairs #KOLEngagement #LifeSciences

000

Lumanity @lumanity.bsky.social · 29/09/2026

Everyone wants to know what's behind the curtain on the Most-Favored-Nation deals. Moira Ringo, VP, Market Access Strategy at Lumanity, shares what to look for beyond the headline in FirstWord PHARMA's “Spotlight On”: price is only one piece. lumanity.com/perspectives...

000

Lumanity @lumanity.bsky.social · 28/09/2026

Every voice in rare disease carries a story—and every story has the power to change things. Watch the full Voices of Rare Disease series: lumanity.com/perspectives... #RareDisease #PatientVoice #VoicesOfRareDisease

Real voices. Real impact. Rare disease, seen clearly. Advocates. Patients. Community builders. Four extraordinary people driving change across rare disease.

000

Lumanity @lumanity.bsky.social · 28/09/2026

Steve Mather shares valuable insights on how IRA revenue horizons, Europe’s JCA, and MFN cross-border pricing dynamics don’t just add complexity - together, they multiply constraints on value and force critical choices earlier than most development playbooks assume. Watch: buff.ly/8gUv1Pp

000

Lumanity @lumanity.bsky.social · 28/09/2026

Will you be at this week's #ISMPPAcademy? Get a first look at the toolkit and gain access to a practical framework to connect evidence, stakeholder needs, and scientific goals. whova.com/web/vowri1FB... #PublicationPlanning #ISMPPAcademy #MedComms #SciComms

000

Lumanity @lumanity.bsky.social · 25/09/2026

We're counting down to the 2026 European Academy of Dermatology & Venereology (EADV) meeting focused on skin and sexual health. Will you be there? Email contact@lumanity.com to find time to connect. For more information on the meeting, visit eadv.org/congress/ #EADV2026 #Dermatology #Venereology

000

Lumanity @lumanity.bsky.social · 25/09/2026

Jillian Cunningham is heading to the annual Cell & Gene Meeting on the Mesa! Don't miss this opportunity to meet with a market access expert who wants to hear about your challenges and opportunities in the cell, gene, and advanced therapy space and share how Lumanity can help.

000

Lumanity @lumanity.bsky.social · 24/09/2026

We are honored to share the story of Krystyn LaBate, PhD in our Voices of Rare Disease series. Krystyn founded the CMCD Foundation to change the lack of resources and awareness her family faced when affected by rare disease. Hear her perspective here. lumanity.com/perspectives...

011

Lumanity @lumanity.bsky.social · 23/09/2026

Ranking KOLs by publication count alone misses the digital opinion leaders & patient advocates who actually move the needle. Multi-signal analytics + 20 yrs of methodology = the right experts, faster. lumanity.com/products/exp... #ExpertNavigator

000

Lumanity @lumanity.bsky.social · 23/09/2026

000

Lumanity @lumanity.bsky.social · 22/09/2026

Will you be at next week's Intellus Worldwide Institute & Awards Celebration? If so, reach out to contact@lumanity.com to find time to meet on-site. For more information about the conference, visit www.intellus.org/Events-Webin... #MarketResearch #MarketInsights #HealthInsights #IntellusInstitute

000

Lumanity @lumanity.bsky.social · 22/09/2026

"They say they believe the data, but they're not prescribing it." That's not an awareness problem. More reach won't fix it. Read why: lumanity.com/perspectives...

000

Lumanity @lumanity.bsky.social · 21/09/2026

Launch experts Andrew Mooney and Laurence Cooper unpack the complexity and pressure of pharma launches for first-time and small organizations. Listen Now: buff.ly/G1ZNENc

000

Lumanity @lumanity.bsky.social · 21/09/2026

Kirsty Tait and Jeff Hart explore how pharmaceutical companies can scale launch excellence as their pipelines grow and complexity increases. Listen now: buff.ly/xfqE3kO

000

Lumanity @lumanity.bsky.social · 18/09/2026

Will you be at the European Association for the Study of #Diabetes (EASD) meeting in Milan? If so, be sure to reach out and connect with who will be in attendance or email contact@lumanity.com to set up time on-site. More information can be found at buff.ly/M1f5QAV #EASD2026 #DiabetesResearch

010

Lumanity @lumanity.bsky.social · 17/09/2026

Our Chief Technology Officer, Anthony Guethert, joined the InformationWeek podcast to talk about managing "compliance cascades"—incidents that originate with a third-party vendor but ripple through an organization and its customers. Listen now: www.informationweek.com/it-leadershi...

000

Lumanity @lumanity.bsky.social · 16/09/2026

In the latest installment of our Voices of Rare Disease series, Krystyn LaBate, PhD reflects on what that rare disease journey taught her and what it will take to truly close the gap for families facing rare neurological conditions. Watch now. lumanity.com/perspectives...

000

Lumanity @lumanity.bsky.social · 15/09/2026

Some KOL databases hold 10M+ names. But more names isn't more clarity—a database tells you who exists, not who fits. Finding the right expert still takes weeks. Here's a better way: lumanity.com/products/exp... #ExpertNavigator

000

Lumanity @lumanity.bsky.social · 15/09/2026

Natalie Thovmasian, Vice President, and Liv Yates, Managing Consultant, speak about how brand positioning is not something left to chance but a strategic compass that shapes how pharma assets are developed, perceived, and adopted. Listen Now: buff.ly/rpdL7oM

000

Lumanity @lumanity.bsky.social · 14/09/2026

We're just a few days away from the European Pharmaceutical Market Research Association (EPHMRA) Switzerland meeting in Basel. Want to connect while at the meeting? Reach out to contact@lumanity.com or directly to Marion Edwards to find time on-site. #EPHMRA #MarketResearch

000

Lumanity @lumanity.bsky.social · 10/09/2026

We're counting down to the 9th Patient-Centered Engagement World Congress 2026 Americas taking place in Boston next week. Email contact@lumanity.com to schedule time to meet. More information: patientcentricitycongress.com #PatientEngagement #PatientCentric #PatientCenteredOutcomes

000

Lumanity @lumanity.bsky.social · 09/09/2026

In the latest installment of our Voices of Rare Disease series, Krystyn LaBate, PhD speaks to the realities families face, where the system still falls short, and how industry, advocates, and caregivers can do better together. Watch her story: buff.ly/1TONLmV #RareDisease #VoicesOfRareDisease

100

Lumanity @lumanity.bsky.social · 31/08/2026

Catch "An Introduction to the ISMPP Publications Practices Committee Strategic Publication Planning Toolkit" at the #ISMPPAcademy! Get a first look at the toolkit and gain access to a practical framework to connect evidence, stakeholder needs, and scientific goals lumanity.com/events/2026-...

000

Lumanity @lumanity.bsky.social · 26/08/2026

Lumanity's Moira Ringo, VP Market Access Strategy, is featured in two APM Market Access interviews unpacking what's really behind the largest annual drop in US Consumer Price Index (CPI) for prescription drugs since 1963. Access the articles here: lumanity.com/perspectives... #MarketAccess #MFN

010

Lumanity @lumanity.bsky.social · 21/08/2026

We are looking forward to the upcoming European Society of Cardiology (ESC) 2026 congress in Munich. If you'll be there, be sure to catch our posters. Details: lumanity.com/events/2026-... Email contact@lumanity.com to schedule time to connect while on-site, or reach out directly to our staff.

000

Lumanity @lumanity.bsky.social · 20/08/2026

Is your team prepared for tough HTA and payer scrutiny? 🔎 Our latest "How To" guide covers building a robust objection handler that can keep affiliates consistent, compliant & confident. lumanity.com/perspectives... #HEOR #MarketAccess #HTA #ValueDossier #ObjectionHandler

000

Lumanity @lumanity.bsky.social · 20/08/2026

Too many Central Nervous System (CNS) programs arrive at payer and regulatory conversations late and underprepared. The science is strong, but the strategy gap is the problem. Learn what separates the programs that succeed from those that stall: buff.ly/mvIXizO

000

Lumanity @lumanity.bsky.social · 19/08/2026

In this new instalment of Lumanity's Patient Progress series, Ebonie Michelle, MPH and Barry Nelson describe what changed their outcomes: not only better tools, but a care model that could actually use those tools—while still treating them as whole people. Read now: lumanity.com/perspectives...

000

Lumanity @lumanity.bsky.social · 13/08/2026

Lumanity has been awarded the Silver APGO Payroll Giving Quality Mark for 2026 by the Charities Trust. We are proud to receive this award that celebrates our decision to foster a culture of philanthropy and committed giving in the workplace by making Payroll Giving available to UK employees.

010

Lumanity @lumanity.bsky.social · 11/08/2026

Rare diseases like Phenylketonuria (PKU) may affect small patient populations, but the impact on individuals and families is profound. Understanding real-world disease burden, treatment patterns, and outcomes has never been more important: buff.ly/Hv6aX5b #PKU #HPA #RWE #RWD #TreatmentPatterns

000

Lumanity @lumanity.bsky.social · 28/07/2026

From 2028, orphan drugs face EU JCA built on RCTs, validated endpoints, and standard of care rare diseases rarely have. Read our new whitepaper exploring how to build a defensible evidence package anyway. lumanity.com/perspectives... #EUHTA #JCA #orphandrug

000

Lumanity @lumanity.bsky.social · 27/07/2026

Will you be in Milan for #ISPEAnnual2026? If so, let's connect! Reach out to contact@lumanity.com to schedule time to meet, or stop by exhibit 307. For a full list of our presentations and attending staff, visit lumanity.com/events/inter... #Pharmacoepidemiology #Epidemiology #RWE #RWD

000

Lumanity @lumanity.bsky.social · 24/07/2026

If you’re designing or commissioning real-world evidence (RWE) studies where the stakes are high, this is required reading. Check out our latest whitepaper: lumanity.com/perspectives... #RWE #RWD #CaseValidation

Text: Stop Guessing: How to Choose and Execute the Right Validation Design for Cases, Exposures, and Outcomes in Real-World Data

Image: Lumanity and PHARMO, part of Lumanity logos

000

Lumanity @lumanity.bsky.social · 22/07/2026

In our latest paper, we highlight the longitudinal, multi-domain linked datasets that are uniquely suited to precision endpoints, rare disease research, and complex study designs — all within robust governance frameworks accepted by the EMA. Read the full paper: lnkd.in/g3WpyR8A #RWE #EMA

Text: Whitepaper on Dutch and Nordic Linked Data to inform Real-World Decisions

000

Lumanity @lumanity.bsky.social · 20/07/2026

Healthcare value propositions risk failure without the specific evidence local payers and HTA bodies demand. Our guide shares insights on validating messaging with experts, identifying weakness, bridging data gaps, and protecting global launch lumanity.com/perspectives... #ValueProposition #HEOR

000

Lumanity @lumanity.bsky.social · 08/07/2026

Having an IEGP isn't the same as having one that works. Our ISPOR session on resilient, cross-functional evidence planning is now available to watch on demand: lumanity.com/perspectives... #HEOR #RWE #MarketAccess #IEGP #ISPORAnnual

010

Lumanity @lumanity.bsky.social · 07/07/2026

We are proud to announce that our near-term science-based greenhouse gas (GHG) emissions reduction targets have been officially validated by the Science Based Targets initiative (SBTi). Read the full press release: lumanity.com/lumanity-str... #SBTi #EmissionsReduction #ClimateCommitment

Lumanity's near-term science-based greenhouse gas emissions reduction targets have officially been validated by the Science Based Targets intiative (SBTi)

000

Lumanity @lumanity.bsky.social · 07/07/2026

Have you seen @Scientist.com’s June pulse check? Lumanity experts join the discussion on how policy in the US and EU, alongside new technologies, are changing the way drugs are priced, evaluated, and brought to market. Read the article here: www.scientist.com/blog/june-20... #HEOR #HTA

000

Lumanity @lumanity.bsky.social · 30/06/2026

Can drug pricing protect affordability and fuel innovation at the same time? In ISPOR's Value & Outcomes Spotlight, Lumanity's Caroline Solon shares her views on one of the toughest balancing acts in healthcare. Read the full article: lumanity.com/perspectives... #DrugPricing #MarketAccess

000

Lumanity @lumanity.bsky.social · 30/06/2026

In honor of Pride Month, we encourage you to check out this clip from Jon Williams, CEO of Lumanity, on what Pride Month means to him and to members of the LGBTQ+ community. Happy Pride! vimeo.com/1205540402?s... #WeAreLumanity #PrideMonth #PrideAtWork

010

Lumanity @lumanity.bsky.social · 25/06/2026

#RealWorldData can be fragmented, hard to interpret, and risky to apply without the right approach. Our #RWE playbook is tailored to your asset, development stage, evidence gaps, target markets, and stakeholder priorities—so guidance is relevant and actionable: buff.ly/X7MukLg #RWD #HTA #RareDisease

000

Lumanity @lumanity.bsky.social · 24/06/2026

How do you turn clinical expertise into quantifiable, HTA-compliant data? Our "How-to" guide provides an overview of Structured Expert Elicitation, a rigorous methodology that can bridge evidence gaps in oncology, rare diseases, and ATMPs. lumanity.com/perspectives... #HEOR #SEE #HTA

000

Lumanity @lumanity.bsky.social · 22/06/2026

Want a deeper look at Lumanity's ISPOR 2026 poster? Our new article expands on our research into cognitive debriefing, breaking down the proposed quantitative thresholds and minimum reporting standards for PRO content validation. lumanity.com/perspectives... #CognitiveDebriefing #PRO

000

Lumanity @lumanity.bsky.social · 17/06/2026

The first JCA report is out, assessing Ipsen’s tovorafenib. Our new article goes beyond the headlines to look at what it confirms and where ambiguity remains from both an operational and evidence assessment view. Read more: lumanity.com/perspectives... #JCA #HTA #MarketAccess

000